Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole Prophylaxis in High-Risk Allo-HSC Patients (POSALLO)
NCT06541067Phase 2Recruiting
- Sponsor
- CHU de Nantes
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of posaconazole in invasive fungal infection (IFI), sponsored by CHU de Nantes. Primary endpoint: Effective residual concentration of posaconazole at Day 8. Started Nov 2024; status: recruiting.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT06541067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541067.